Embryo–Fetal Development and Maternal–Fetal Exposure of the Von Willebrand Factor Binding Aptamer Rondaptivon Pegol (BT200) in Rabbits
Nucleic Acid Therapeutics · 2026
DOI: 10.1177/21593337261476421 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, 2026. Verfasst von Katarina D Kovacevic Miljević und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, von Willebrand Factor, Fetal Development, Embryonic Development. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Band Therapeutics.
Abstract (Originalsprache)
Rondaptivon pegol (BT200) is a PEGylated RNA aptamer that prolongs von Willebrand factor (VWF) and factor VIII half-lives in patients with hemophilia A and von Willebrand disease (VWD) type 2B. Embryo–fetal safety is particularly relevant given the disproportionate disease burden in women with VWD. Data on placental transfer and developmental safety of PEGylated aptamers remain limited. An embryo–fetal development study was conducted in pregnant rabbits. Animals received rondaptivon pegol subcutaneously (0, 1.5, 5, or 15 mg/kg/day) from gestational days (GDs) 7–19. Maternal toxicokinetic samples and pooled fetal plasma concentrations were collected during gestation to quantify transplacental exposure. Rondaptivon pegol was well tolerated, with no maternal toxicity, no effects on implantation, and no treatment-related fetal malformations. Dose-related reductions in mean fetal body weight (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
- Band Therapeutics LLC, Lexington, Massachusetts, USA.
- ICON plc, Edinburgh, UK.
- PMT Pharma Consulting, Worcester, Massachusetts, USA.
ORCID-Profile: Katarina D Kovacevic Miljević
Förderung
- Band Therapeutics
Zitieren
APA
Kovacevic Miljević, K. D., Zhu, S., Gilbert, J. C., Harvey, W., Tarantino, P., & Jilma, B. (2026). Embryo–Fetal Development and Maternal–Fetal Exposure of the Von Willebrand Factor Binding Aptamer Rondaptivon Pegol (BT200) in Rabbits. Nucleic Acid Therapeutics. https://doi.org/10.1177/21593337261476421
Vancouver
Kovacevic Miljević KD, Zhu S, Gilbert JC, Harvey W, Tarantino P, Jilma B. Embryo–Fetal Development and Maternal–Fetal Exposure of the Von Willebrand Factor Binding Aptamer Rondaptivon Pegol (BT200) in Rabbits. Nucleic Acid Therapeutics. 2026. doi:10.1177/21593337261476421
BibTeX
@article{KovacevicMiljevi2026,
author = {Kovacevic Miljević, Katarina D and Zhu, Shuhao and Gilbert, James C and Harvey, Warren and Tarantino, Paul and Jilma, Bernd},
title = {Embryo–Fetal Development and Maternal–Fetal Exposure of the Von Willebrand Factor Binding Aptamer Rondaptivon Pegol (BT200) in Rabbits},
journal = {Nucleic Acid Therapeutics},
year = {2026},
doi = {10.1177/21593337261476421}
}
EUVIMED